Publications by C3PA staff
(Priston, Rigby-Jones)
1. Priston MJ, Hughes JM, Santillo M, Christie IW. Stability of an epidural analgesic admixture containing epinephrine, fentanyl and bupivacaine. Anaesthesia 59 (10):979-83 (2004).
2. Priston MJ, Grant IC, Hughes JM and Marquis PT. Pilot study on potential degradation of drug efficacy resulting from Antarctic storage, transport and field conditions. Int. J. Circumpolar Health 64:2 (2005).
3. Rigby-Jones AE, Priston MJ, Sneyd JR, Murray DM, Thorne GC, Tooley MA, Wolf AR. Pharmacokinetics and Pharmacodynamics of Propofol in Critically Ill Children. Eur J Anaesthesiol 22 (S34): 144 (2005).
4. Rigby-Jones AE, Priston MJ, Wolf AR, Sneyd JR. Concentration-dependent instability of propofol in whole human blood. Eur J Anaesthesiol 22 (S34): 122 (2005).
5. Rigby-Jones, AE, Priston, MJ, Thorne, GC, Tooley, MA, Sneyd, JR, Wolf, AR. Population pharmacokinetics of remifentanil in critically ill post cardiac neonates, infants and children. British Journal of Anaesthesia (2005) 95(4):578P-579P.
6. Teare LJ, Zajicek JR, Priston M, Wright D. The relationship between cannabinoid levels and clinical effect in multiple sclerosis. Multiple Sclerosis 2005; 11: S90, Suppl. 1.
7. Teare, LJ, Zajicek, JP, Wright, D, Priston, M. Do blood levels explain clinical differences between whole extract of cannabis and pure delta-9-tetrahydrocannabinol in the treatment of multiple sclerosis symptoms? Journal of Neurology (2005) 252 (Suppl.2):110.
8. Rigby-Jones AE, Sneyd JR, Absalom AR. Ketamine pharmacokinetics in healthy volunteers: A pooled population analysis. SIVA UK Meeting, Edinburgh, November 2005. Anaesthesia, In press.
9. WM Ingram, MJ Priston, GJ Sewell. Improved assay for R(-)-apomorphine with application to clinical pharmacokinetic studies in Parkinson’s disease. Chromatogr B Analyt Technol Biomed Life Sci. 2006; 831(1-2):1-7.
10. Teare LJ, Zajicek JP, Wright D, Priston M. Correlations between cannabinoid levels and the Ashworth Score Support results from the CAMS trial. J Neurol Neurosurg Psy 2006; 77(1):07.
11. Rigby-Jones AE, Priston MJ, Sneyd JR , Wolf AR. Pharmacokinetics of remifentanil sedation in paediatric intensive care. Eur J Anaesthesiol 2006; 23 (S37): 171.
12. Rigby-Jones AE, Sneyd JR, Absalom AR. Ketamine pharmacokinetics in healthy volunteers: Model Evaluation. Abstract accepted for presentation at the SIVA UK Meeting, Chepstow, November 2006.
13. A McCabe, AE Rigby-Jones, MJ Priston, GC Thorne, JR Sneyd, AR Wolf. Remifentanil infusions for sedation in PICU: Correlation of infusion rate, whole blood concentration and Comfort Score. Pediatric Critical Care Medicine 2006; 7(4):411.
14. Rigby-Jones AE, Priston MJ, Wolf AR, Sneyd JR. 34th Annual Scientific Meeting of the Association of Paediatric Anaesthetists of Great Britain and Ireland, 8-10 March 2007, Manchester. Paediatric propofol pharmacokinetics: a multicentre study. Pediatric Anesthesia 2007; 17 (6), 610–610.
15. Rigby-Jones AE, Priston MJ, Sneyd JR, McCabe AP, Davis GI, Tooley MA, Thorne GC, Wolf AR. Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. British Journal of Anaesthesia 2007; 99(2):252-261.
16. M. J. Priston, J. Hughes, A. E. Rigby-Jones and J. R. Sneyd. Plasticizer release (DEHP) from TIVA infusion sets. British Journal of Anaesthesia 2007; 99 (5): 765P.
17. R. J. Rose, M. J. Priston, A. E. Rigby-Jones and J. R. Sneyd. Effect of temperature on plasticizer release
[di(2-ethylhexyl)phthalate] from TIVA infusion sets. British Journal of Anaesthesia 2009; 102 (4): 581-2P.
18. Rigby-Jones AE, Sneyd JR, Vijn P, Boen P, Cross M. First administration to man of Org 25435, an new intravenous anaesthetic: A Phase 1 Clinical Trial. BMC Anesthesiology 2010;10:10
19. A.E. Rigby-Jones and J.R. Sneyd. New drugs and technologies, intravenous anaesthesia is on the move (again). Br. J. Anaesth. 2010; 105(3): 246-254.
20. Rigby-Jones AE, Sneyd JR. Propofol and children – what we know and what we do not know. Pediatric Anesthesia 2011; 21(3): 247–254.
2. Priston MJ, Grant IC, Hughes JM and Marquis PT. Pilot study on potential degradation of drug efficacy resulting from Antarctic storage, transport and field conditions. Int. J. Circumpolar Health 64:2 (2005).
3. Rigby-Jones AE, Priston MJ, Sneyd JR, Murray DM, Thorne GC, Tooley MA, Wolf AR. Pharmacokinetics and Pharmacodynamics of Propofol in Critically Ill Children. Eur J Anaesthesiol 22 (S34): 144 (2005).
4. Rigby-Jones AE, Priston MJ, Wolf AR, Sneyd JR. Concentration-dependent instability of propofol in whole human blood. Eur J Anaesthesiol 22 (S34): 122 (2005).
5. Rigby-Jones, AE, Priston, MJ, Thorne, GC, Tooley, MA, Sneyd, JR, Wolf, AR. Population pharmacokinetics of remifentanil in critically ill post cardiac neonates, infants and children. British Journal of Anaesthesia (2005) 95(4):578P-579P.
6. Teare LJ, Zajicek JR, Priston M, Wright D. The relationship between cannabinoid levels and clinical effect in multiple sclerosis. Multiple Sclerosis 2005; 11: S90, Suppl. 1.
7. Teare, LJ, Zajicek, JP, Wright, D, Priston, M. Do blood levels explain clinical differences between whole extract of cannabis and pure delta-9-tetrahydrocannabinol in the treatment of multiple sclerosis symptoms? Journal of Neurology (2005) 252 (Suppl.2):110.
8. Rigby-Jones AE, Sneyd JR, Absalom AR. Ketamine pharmacokinetics in healthy volunteers: A pooled population analysis. SIVA UK Meeting, Edinburgh, November 2005. Anaesthesia, In press.
9. WM Ingram, MJ Priston, GJ Sewell. Improved assay for R(-)-apomorphine with application to clinical pharmacokinetic studies in Parkinson’s disease. Chromatogr B Analyt Technol Biomed Life Sci. 2006; 831(1-2):1-7.
10. Teare LJ, Zajicek JP, Wright D, Priston M. Correlations between cannabinoid levels and the Ashworth Score Support results from the CAMS trial. J Neurol Neurosurg Psy 2006; 77(1):07.
11. Rigby-Jones AE, Priston MJ, Sneyd JR , Wolf AR. Pharmacokinetics of remifentanil sedation in paediatric intensive care. Eur J Anaesthesiol 2006; 23 (S37): 171.
12. Rigby-Jones AE, Sneyd JR, Absalom AR. Ketamine pharmacokinetics in healthy volunteers: Model Evaluation. Abstract accepted for presentation at the SIVA UK Meeting, Chepstow, November 2006.
13. A McCabe, AE Rigby-Jones, MJ Priston, GC Thorne, JR Sneyd, AR Wolf. Remifentanil infusions for sedation in PICU: Correlation of infusion rate, whole blood concentration and Comfort Score. Pediatric Critical Care Medicine 2006; 7(4):411.
14. Rigby-Jones AE, Priston MJ, Wolf AR, Sneyd JR. 34th Annual Scientific Meeting of the Association of Paediatric Anaesthetists of Great Britain and Ireland, 8-10 March 2007, Manchester. Paediatric propofol pharmacokinetics: a multicentre study. Pediatric Anesthesia 2007; 17 (6), 610–610.
15. Rigby-Jones AE, Priston MJ, Sneyd JR, McCabe AP, Davis GI, Tooley MA, Thorne GC, Wolf AR. Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. British Journal of Anaesthesia 2007; 99(2):252-261.
16. M. J. Priston, J. Hughes, A. E. Rigby-Jones and J. R. Sneyd. Plasticizer release (DEHP) from TIVA infusion sets. British Journal of Anaesthesia 2007; 99 (5): 765P.
17. R. J. Rose, M. J. Priston, A. E. Rigby-Jones and J. R. Sneyd. Effect of temperature on plasticizer release
[di(2-ethylhexyl)phthalate] from TIVA infusion sets. British Journal of Anaesthesia 2009; 102 (4): 581-2P.
18. Rigby-Jones AE, Sneyd JR, Vijn P, Boen P, Cross M. First administration to man of Org 25435, an new intravenous anaesthetic: A Phase 1 Clinical Trial. BMC Anesthesiology 2010;10:10
19. A.E. Rigby-Jones and J.R. Sneyd. New drugs and technologies, intravenous anaesthesia is on the move (again). Br. J. Anaesth. 2010; 105(3): 246-254.
20. Rigby-Jones AE, Sneyd JR. Propofol and children – what we know and what we do not know. Pediatric Anesthesia 2011; 21(3): 247–254.
